WVE Stock — Wave Life Sciences Ltd.

Wave Life Sciences Ltd. (WVE)

Updated October 16, 2026.

WVE is a Stock. Total return is -80.4% over the past 10.9 years, 419.9 points behind SPY at 339.5%.

Wave Life Sciences is a clinical-stage biotechnology company developing RNA-based medicines to treat rare and common diseases, including obesity, alpha-1 antitrypsin deficiency, liver disease, muscular dystrophy, and Huntington's disease through its proprietary PRISM platform. As a pre-revenue company focused on drug development rather than established commercial operations, it does not currently distribute income to shareholders. The company appeals to investors seeking exposure to biotechnology innovation and the potential for significant capital appreciation, though it carries the substantial risk inherent in early-stage drug development.

WVE performance versus SPY

Price and return data through 2026-10-16.

Total return is -80.4% over the past 10.9 years, 419.9 points behind SPY at 339.5%. Over the past year its total return — price change plus distributions reinvested — is -60.2%. Its deepest 1-year drawdown was 85.5%.

WVE key facts

Asset type

Stock

Asset class

Equity

Inception date

11/11/2015

Distribution frequency

None

Last close

$3.13 (as of 2026-10-16)

Market cap

$616,760,788

Average volume

3281706.0

Beta

-1.428

Payout ratio

0.0%

EPS

$-1.08

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

WVE risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 85.5%.

Who may consider WVE — and who may not

It is a weaker fit for investors who need monthly cash flow (WVE does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on WVE

• All tickers starting with W

Tagged: Healthcare.

Frequently asked questions